IntraBiotics Pharmaceuticals

[Luna]

Intrabiotics (IBPI) hat ausgespült.
Die heutige Meldung, ein beinahe Todesstoss für das Unternehmen. Der Ofen ist jedenfalls für längere Zeit aus.

"Iseganan HCI-Mundspülung" zur Vorbeugung gegen orale Mucositis (Entzündung der Mundschleimhaut), hat bei Patienten während einer hoch dosierten Chemotherapie, den primären Endpunkt nicht erreicht.

Dies kommt uns doch bekannt vor . Bereits im Mai zeigten Ergebnisse keinen Unterschied zu dem Plazebo-Vergleich. Man entschied sich aber zu einer weiteren Studie mit 509 Patienten.
Ein Blick auf die Pipeline macht das Desaster deutlich. Die Forschungen wurden voll auf Iseganan fixiert. Wie es jetzt weiter geht, weiss nur der liebe Gott.

http://www.intrabiotics.com/products/media/pipeline_chart.gif
Mindestens der oberste Kandidat kann gestrichen werden. Ob die anderen Anwendungen mit hohem Elan weitergeführt werden, bleibt fraglich.


...und noch ein Blick auf den Chart. Heute geschlossen bei 1.57 USD. Nachbörslich auf 0.61 USD. -60%
http://chart.bigcharts.com/bc3/intchart/frames/chart.asp?symb=ibpi&compidx=aaaaa%3A0&ma=0&maval=9&uf=7168&lf=1&lf2=4&lf3=0&type=64&size=2&state=11&sid=1420765&style=350&time=8&freq=1&nosettings=1&rand=963&mocktick=1

[Ca$hmandt]

Hier noch mal die Orginalmeldung zu lunas bericht:

IntraBiotics Pharmaceuticals, Inc. , today announced preliminary results of its 509 patient Phase III clinical trial of its lead product, iseganan hydrochloride (HCl) oral solution, in reducing the incidence and severity of ulcerative oral mucositis in patients undergoing high-dose chemotherapy for the treatment of cancer. These results indicated that iseganan did not meet its primary endpoint of reducing oral mucositis.

The study''s primary endpoint was the proportion of patients who did not develop severe oral mucositis (defined as NCI CTC stomatitis Grade 1 or less, meaning patients did not experience painful lesions of their oral cavity) during chemotherapy in the iseganan group versus placebo. 43% of patients in the iseganan arm did not develop severe oral mucositis versus 37% of patients in the placebo group, a difference that did not reach statistical significance (p=0.18).

Secondary analyses predefined by the protocol included reduction in pain, swallowing difficulty, the proportion of patients who developed ulcerative oral mucositis, narcotic use and the severity of oral mucositis during chemotherapy. The study''s secondary endpoints trended in favor of iseganan, but did not achieve statistical significance. Iseganan was well tolerated by this group of cancer patients, corroborating earlier findings of the safety of oral-topical application of iseganan.

"Clearly we are disappointed that iseganan failed to show a statistically significant benefit in treating severe oral mucositis in patients receiving high dose chemotherapy," said Dr. Ernest Mario, Chairman and Chief Executive Officer. "We chose severe oral mucositis as a primary indication for iseganan because it represents a huge unmet medical need. Unfortunately, while iseganan appeared to show some benefit in this patient setting, the benefit was not statistically significant. As a result, we will cease the pursuit of severe oral mucositis as an indication for iseganan."


About Iseganan

Iseganan hydrochloride (HCl) oral solution is a potent, broad-spectrum, fast-acting antibiotic that functions by a novel mechanism of action, substantially reducing the likelihood of microbial resistance. It is the first in a new class of antibiotic peptide drugs known as protegrins, which are naturally-occurring substances found in mammals where they form part of the first line of defense against invading bacteria and fungi.

Iseganan is also in clinical development for prevention of ventilator-associated pneumonia (VAP) the most common infection occurring among patients in the intensive care unit. Iseganan is also being developed as a treatment of respiratory infections associated with cystic fibrosis. These indications represent substantial clinical and market opportunities.

[Ca$hmandt]

IntraBiotics Aktien fallen zur Stunde um 70.7 Prozent oder 1.11 Dollar auf 46 cents, nachdem das Medikament Iseganan nicht die primären Ziele aus der Test Phase III erreichen konnte. 43 Prozent der Patienten in der Testphase zeigten eine Verbesserung, verglichen mit 37 Prozent in der Placebo Gruppe.

© BörseGo

[the mind]

ein beinahe Todesstoss für das Unternehmen

.....und sie kam wieder! :eek: IBPI (13,86$) sieht mittelfristig gut aus, zumindest charttechnisch ;) - sollte auf den volume-screener :D

http://chart.bigcharts.com/bc3/intchart/frames/chart.asp?symb=ibpi&compidx=aaaaa%3A0&ma=1&maval=22%2C50%2C100%2C200&uf=8&lf=268435456&lf2=32&lf3=1024&type=4&size=2&state=11&sid=1420765&style=320&time=7&freq=1&comp=NO%5FSYMBOL%5FCHOSEN&nosettings=1&rand=6651&mocktick=1

[the mind]

das war der breakaway-gap-verursacher: :D

FDA Grants Fast Track Designation for IntraBiotics' Iseganan (http://biz.yahoo.com/prnews/030905/sff010_1.html)

ein weiterer impuls kam vom 19mio$-private placement (http://biz.yahoo.com/prnews/031006/sfm133_1.html)